Joshua Greally
Scientific Business Development Manager Sygnature Discovery
Joshua Greally is an ADC Discovery Consultant at Sygnature Discovery, where he works with biotech and pharmaceutical companies to advance next-generation antibody-drug conjugates (ADCs). With more than a decade of experience in drug discovery, spanning medicinal chemistry, bioconjugation, and ADC development, he provides scientific, competitive, and strategic insights to support innovative therapeutic programs. Prior to joining Sygnature, Joshua held scientific leadership roles at BiVictriX Therapeutics and completed doctoral research at The University of Manchester focused on novel cancer therapies. He is passionate about integrating biology, chemistry, and translational science to enable the development of safer, more effective ADCs.
Seminars
- Understanding how to migrate from non-selective ADC payloads
- Debating the right properties for a next-generation payload and linker: Can (or should?) any small molecule therapeutic be developed into an ADC?
- Debating the right strategy for dual payload ADCs
- Understanding ADC toxicity and developability for next generation conjugates
